Sale!

Fintepla Fenfluramine HCl 2.2MG/ML

$230.67

+ Free Shipping(orders above 500$)
FINTEPLA (fenfluramine Hcl oral sln),buy fintepla online without prescription, order fintepla online
  • Manufacturer: ZOGENIX INC
    Approval date: June 25, 2020
    Strength(s): EQ 2.2MG BASE/ML
  • Brand Name: Fenfluramine

Generic Fintepla Availability

Last updated on Aug 10, 2022.

Fintepla is a brand name of fenfluramine, approved by the FDA in the following formulation(s):

FINTEPLA (fenfluramine hydrochloride – solution;oral)

  • Manufacturer: ZOGENIX INC
    Approval date: June 25, 2020
    Strength(s): EQ 2.2MG BASE/ML

Has a generic version of Fintepla been approved?

No. There is currently no therapeutically equivalent version of Fintepla available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Fintepla. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug’s development and may include a wide range of claims.

  • Patent 10,452,815
    Patent expiration dates:

    • June 29, 2038
      ✓ Patent use: USE OF CARDIAC MONITORING AND RESTRICTED DISTRIBUTION OF FENFLURAMINE TO MITIGATE RISK OF CARDIOVASCULAR TOXICITY IN THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME
  • Patent 10452815*
    Patent expiration dates:

    • December 29, 2038
  • Patent 10,478,441
    Patent expiration dates:

    • May 3, 2033
      ✓ Patent use: USE IN COMBINATION WITH STIRIPENTOL FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME
  • Patent 10478441*
    Patent expiration dates:

    • November 3, 2033
  • Patent 10,478,442
    Patent expiration dates:

    • May 3, 2033
      ✓ Patent use: USE IN COMBINATION WITH STIRIPENTOL FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME
  • Patent 10478442*
    Patent expiration dates:

    • November 3, 2033
  • Patent 10,603,290
    Patent expiration dates:

    • August 2, 2037
      ✓ Patent use: USE IN COMBINATION WITH CANNABIDIOL FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME
    • August 2, 2037
      ✓ Patent use: USE IN COMBINATION WITH CANNABIDIOL FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME
  • Patent 10603290*
    Patent expiration dates:

    • February 2, 2038
  • Patent 10,947,183
    Patent expiration dates:

    • December 20, 2036
      ✓ Drug substance
      ✓ Drug product
  • Patent 10947183*
    Patent expiration dates:

    • June 20, 2037
  • Patent 10,950,331
    Patent expiration dates:

    • September 28, 2035
      ✓ Patent use: TREATMENT OF REFRACTORY EPILEPSY PATIENTS WITH FENFLURAMINE THAT REDUCES THE RISK OF CARDIOVASCULAR TOXICITY BY USING CARDIAC MONITORING AND RESTRICTED DISTRIBUTION
  • Patent 10950331*
    Patent expiration dates:

    • March 28, 2036
  • Patent 11,040,018
    Patent expiration dates:

    • August 2, 2037
      ✓ Patent use: USE IN COMBINATION WITH CANNABIDIOL FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME
    • August 2, 2037
      ✓ Patent use: USE IN COMBINATION WITH CANNABIDIOL FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME
  • Patent 11040018*
    Patent expiration dates:

    • February 2, 2038
  • Method for the treatment of dravet syndrome
    Patent 9,549,909
    Issued: January 24, 2017
    Assignee(s): The Katholieke Universiteit Leuven University Hospital Antwerp
    A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day.Patent expiration dates:

    • May 3, 2033

Reviews

There are no reviews yet.

Be the first to review “Fintepla Fenfluramine HCl 2.2MG/ML”

Your email address will not be published.

Shopping Cart
Open chat
Weight loss home
Welcome to your favorite weight loss home. How can we help you achieve your dream body?